Avelumab and pembrolizumab for the treatment of merkel cell carcinoma
Sandra D'Angelo et al.
Genetic evolution of NSCLC
Response rates to immunotherapy in sarcoma patients and implications for future therapies
Double immunotherapy with durvalumab and tremelimumab versus quadruple therapy in NSCLC
Results of the combined inhibition of IDO1 and PD-L1 in locally advanced or metastatic solid tumors